CompletedNCT00114686
Quetiapine with mood stabilizers for alcohol dependence in bipolarity
About this title
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
Read the official source — NCT00114686This study evaluated the safety and effectiveness of Quetiapine fumarate for people with bipolarity.
Medication studyAges 21–60United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Quetiapine fumarate for people with bipolarity.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 21 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 37 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 350
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 21 Years to 60 Years
- Official registry ID
- NCT00114686
- Official title
Show the full official title
A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos · San Diego · New Haven
35 more locations
- Jacksonville
- Maitland
- Orlando
- Eagle
- Shreveport
- Glen Burnie
- Boston
- St Louis
- Moorestown
- Albuquerque
- New York
- Staten Island
- The Bronx
- Chapel Hill
- Research Triangle Park
- Cincinnati
- Cleveland
- Dayton
- Portland
- Media
- Philadelphia
- Pittsburgh
- Columbia
- Memphis
- Nashville
- Austin
- Dallas
- Houston
- San Antonio
- Wichita Falls
- Richmond
- Bellevue
- Kirkland
- Seattle
- Milwaukee
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Quetiapine fumarate for people with bipolarity.
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate, lithium and divalproex.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 21 years to 60 years. Other eligibility criteria applied.
